ConforMIS (CFMS) Getting Somewhat Favorable Media Coverage, Study Finds

Media stories about ConforMIS (NASDAQ:CFMS) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ConforMIS earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.4305253417963 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of ConforMIS (NASDAQ:CFMS) traded down $0.04 on Friday, reaching $2.46. The company had a trading volume of 258,500 shares, compared to its average volume of 332,286. The stock has a market cap of $113.23, a PE ratio of -1.84 and a beta of 2.21. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.19 and a quick ratio of 5.38. ConforMIS has a twelve month low of $2.21 and a twelve month high of $8.72.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. ConforMIS had a negative return on equity of 76.88% and a negative net margin of 72.70%. The firm had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same quarter last year, the firm posted ($0.31) EPS. The company’s revenue was down 1.3% compared to the same quarter last year. research analysts predict that ConforMIS will post -1.27 earnings per share for the current year.

Several research analysts have recently weighed in on the company. ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. BTIG Research reiterated a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. Finally, Zacks Investment Research downgraded ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $5.54.

In other ConforMIS news, CTO Daniel Steines sold 15,485 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $3.15, for a total value of $48,777.75. Following the sale, the chief technology officer now owns 254,652 shares of the company’s stock, valued at approximately $802,153.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Paul S. Weiner sold 17,723 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total value of $56,181.91. Following the completion of the sale, the chief financial officer now directly owns 162,009 shares in the company, valued at approximately $513,568.53. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,994 shares of company stock worth $244,696. Insiders own 9.55% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ConforMIS (CFMS) Getting Somewhat Favorable Media Coverage, Study Finds” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/29/conformis-cfms-getting-somewhat-favorable-media-coverage-study-finds.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit